Literature DB >> 27245781

Sex-specific effects of relaxin-3 on food intake and body weight gain.

Juliane Calvez1, Camila de Ávila1, Elena Timofeeva1.   

Abstract

Relaxin-3 (RLN3) is a neuropeptide that is strongly expressed in the pontine nucleus incertus (NI) and binds with high affinity to its cognate receptor RXFP3. Central administration of RLN3 in rats increases food intake and adiposity. In humans, RLN3 polymorphism has been associated with obesity and hypercholesterolaemia. Emerging evidence suggests that the effects of RLN3 may have sex-specific aspects. Thus, the RLN3 knockout female but not male mice are hypoactive. RLN3 produced stronger orexigenic and obesogenic effects in female rats compared with male rats. In addition, female rats demonstrated higher sensitivity to lower doses of RLN3. Repeated cycles of food restriction and stress were accompanied by an increase in RLN3 expression and hyperphagia in female but not in male rats. Furthermore, stress-induced binge eating in female rats was blocked by an RXFP3 receptor antagonist. RLN3 increased the expression of corticotropin releasing factor in the paraventricular hypothalamic nucleus in male but not in female rats. Conversely, in female rats, RLN3 increased the expression of orexin in the lateral hypothalamus. There is evidence that orexin directly activates the RLN3 neurons in the NI. The positive reinforcement of the RLN3 effects by orexin may intensify behavioural activation and feeding in females. Sex-specific effects of RLN3 may also depend on differential expression of RXFP3 receptors in the brain. Given the higher sensitivity of females to the orexigenic effects of RLN3 and the stress-induced activation of RLN3, the overall data suggest a possible role for RLN3 in eating disorders that show a higher propensity in women. LINKED ARTICLES: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.
© 2016 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27245781      PMCID: PMC5406289          DOI: 10.1111/bph.13530

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  114 in total

1.  Central injection of relaxin-3 receptor (RXFP3) antagonist peptides reduces motivated food seeking and consumption in C57BL/6J mice.

Authors:  Craig M Smith; Berenice E Chua; Cary Zhang; Andrew W Walker; Mouna Haidar; David Hawkes; Fazel Shabanpoor; Mohammad Akhter Hossain; John D Wade; K Johan Rosengren; Andrew L Gundlach
Journal:  Behav Brain Res       Date:  2014-03-25       Impact factor: 3.332

2.  Nucleus incertus inactivation impairs spatial learning and memory in rats.

Authors:  Mohsen Nategh; Sara Nikseresht; Fariba Khodagholi; Fereshteh Motamedi
Journal:  Physiol Behav       Date:  2014-11-08

Review 3.  Pharmacological interventions for geriatric cachexia: a narrative review of the literature.

Authors:  A Yaxley; M D Miller; R J Fraser; L Cobiac
Journal:  J Nutr Health Aging       Date:  2012-02       Impact factor: 4.075

4.  A role for lateral hypothalamic orexin neurons in reward seeking.

Authors:  Glenda C Harris; Mathieu Wimmer; Gary Aston-Jones
Journal:  Nature       Date:  2005-08-14       Impact factor: 49.962

5.  Amygdaloid-lesion hyperphagia: impaired response to caloric challenges and altered macronutrient selection.

Authors:  B M King; K N Rossiter; S G Stines; G M Zaharan; J T Cook; M D Humphries; D A York
Journal:  Am J Physiol       Date:  1998-08

6.  Abnormal weight gain in rats with amygdaloid lesions.

Authors:  B M King; J M Kass; K L Neville; H Sam; A C Tatford; C A Zansler
Journal:  Physiol Behav       Date:  1993-09

7.  Behavioral phenotyping of mixed background (129S5:B6) relaxin-3 knockout mice.

Authors:  Craig M Smith; Andrew J Lawrence; Steve W Sutton; Andrew L Gundlach
Journal:  Ann N Y Acad Sci       Date:  2009-04       Impact factor: 5.691

8.  Metabolic and neuroendocrine responses to RXFP3 modulation in the central nervous system.

Authors:  Steven W Sutton; Jonathan Shelton; Craig Smith; John Williams; Sujin Yun; Timothy Motley; Chester Kuei; Pascal Bonaventure; Andrew Gundlach; Changlu Liu; Timothy Lovenberg
Journal:  Ann N Y Acad Sci       Date:  2009-04       Impact factor: 5.691

9.  Oxytocin receptor mRNA expression in the ventromedial hypothalamus during the estrous cycle.

Authors:  T L Bale; D M Dorsa; C A Johnston
Journal:  J Neurosci       Date:  1995-07       Impact factor: 6.167

10.  Identification of relaxin-3/INSL7 as a ligand for GPCR142.

Authors:  Changlu Liu; Jingcai Chen; Steven Sutton; Barbara Roland; Chester Kuei; Niven Farmer; Rannar Sillard; Timothy W Lovenberg
Journal:  J Biol Chem       Date:  2003-09-30       Impact factor: 5.157

View more
  10 in total

1.  Recent progress in the understanding of relaxin family peptides and their receptors.

Authors:  R J Summers
Journal:  Br J Pharmacol       Date:  2017-05       Impact factor: 8.739

Review 2.  Distribution, physiology and pharmacology of relaxin-3/RXFP3 systems in brain.

Authors:  Sherie Ma; Craig M Smith; Anna Blasiak; Andrew L Gundlach
Journal:  Br J Pharmacol       Date:  2016-12-04       Impact factor: 8.739

3.  Impacts of seasonality on gene expression in the Chinese horseshoe bat.

Authors:  Wenli Chen; Xiuguang Mao
Journal:  Ecol Evol       Date:  2022-05-13       Impact factor: 3.167

Review 4.  The Relaxin-3 Receptor, RXFP3, Is a Modulator of Aging-Related Disease.

Authors:  Hanne Leysen; Deborah Walter; Lore Clauwaert; Lieselot Hellemans; Jaana van Gastel; Lakshmi Vasudevan; Bronwen Martin; Stuart Maudsley
Journal:  Int J Mol Sci       Date:  2022-04-15       Impact factor: 6.208

5.  Development of a selective agonist for relaxin family peptide receptor 3.

Authors:  Dian Wei; Meng-Jun Hu; Xiao-Xia Shao; Jia-Hui Wang; Wei-Han Nie; Ya-Li Liu; Zeng-Guang Xu; Zhan-Yun Guo
Journal:  Sci Rep       Date:  2017-06-12       Impact factor: 4.379

6.  Intranasal administration of a stapled relaxin-3 mimetic has anxiolytic- and antidepressant-like activity in rats.

Authors:  Subhi Marwari; Anders Poulsen; Norrapat Shih; Rajamani Lakshminarayanan; R Manjunatha Kini; Charles William Johannes; Brian William Dymock; Gavin Stewart Dawe
Journal:  Br J Pharmacol       Date:  2019-09-11       Impact factor: 8.739

7.  Involvement of the Nucleus Incertus and Relaxin-3/RXFP3 Signaling System in Explicit and Implicit Memory.

Authors:  Isis Gil-Miravet; Aroa Mañas-Ojeda; Francisco Ros-Bernal; Esther Castillo-Gómez; Hector Albert-Gascó; Andrew L Gundlach; Francisco E Olucha-Bordonau
Journal:  Front Neuroanat       Date:  2021-03-18       Impact factor: 3.856

Review 8.  Anxiety and Depression: What Do We Know of Neuropeptides?

Authors:  Ida Kupcova; Lubos Danisovic; Ivan Grgac; Stefan Harsanyi
Journal:  Behav Sci (Basel)       Date:  2022-07-29

Review 9.  Corticotropin-releasing factor system in the lateral septum: Implications in the pathophysiology of obesity.

Authors:  Rossy Olivares-Barraza; José Luis Marcos; Jonathan Martínez-Pinto; Marco Fuenzalida; Javier A Bravo; Katia Gysling; Ramón Sotomayor-Zárate
Journal:  Front Mol Neurosci       Date:  2022-09-20       Impact factor: 6.261

10.  RLN3/RXFP3 Signaling in the PVN Inhibits Magnocellular Neurons via M-like Current Activation and Contributes to Binge Eating Behavior.

Authors:  Alan Kania; Agata Szlaga; Patryk Sambak; Anna Gugula; Ewa Blasiak; Maria Vittoria Micioni Di Bonaventura; Mohammad Akhter Hossain; Carlo Cifani; Grzegorz Hess; Andrew L Gundlach; Anna Blasiak
Journal:  J Neurosci       Date:  2020-06-12       Impact factor: 6.167

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.